Differentiated vulvar intraepithelial neoplasia is a unique precursor to vulvar squamous cell carcinoma that is typically HPV-negative and frequently associated with nuclear p53 staining. These features imply a mode of pathogenesis involving somatic mutations. However, the genetic relationship of differentiated vulvar intraepithelial neoplasm and vulvar squamous cell carcinoma and the role of Tp53 mutations in this process have not been resolved. We analyzed 11 differentiated vulvar intraepithelial neoplasms and 6 associated vulvar squamous cell carcinomas. Sections were stained for p53 and p63 and DNA from multiple epithelial sites, representing normal control tissues (n ¼ 10), differentiated vulvar intraepithelial neoplasias (n ¼ 18), and vulvar squamous cell carcinomas (n ¼ 6), were obtained by laser capture microdissection, and sequenced for exons 2-11 of Tp53. Six of 10 cases contained at least one Tp53 mutation-positive differentiated vulvar intraepithelial neoplasia focus; 4 strongly p53 immuno-positive and 2 negative. Staining for p53 and p63 co-localized, targeting the immature epithelium, but surface epithelium was Tp53 mutation-positive. Four of five vulvar squamous cell carcinomas were Tp53 mutation-positive; two shared identical Tp53 mutation with adjacent differentiated vulvar intraepithelial neoplasia. Disparate foci of differentiated vulvar intraepithelial neoplasia often showed different mutations consistent with multiple neoplastic clones. Differentiated vulvar intraepithelial neoplasia is, with few exceptions, associated with Tp53 mutations and will be p53 immunopositive when missense mutations (versus some nonsense and all deletion mutations) are present. Multiple Tp53 mutations in different sites supports the presence of multiple independent genetic events, but shared Tp53 mutations in both differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma support a genetic relationship between the two. The confinement of p53 staining to immature cell nuclei is consistent with maturation-dependent degradation of mutant p53 protein.
Mutation of the tumor suppressor Tp53 gene is the most common cancer-related genetic change in humans. 1 In the lower female genital tract, it is uncommon in the cervix, in which human papillomavirus (HPV) is the causative agent in more than 90% of tumors. In the vulva, approximately 40% of malignancies can be linked to HPV. 2 In this HPVmediated pathway, E6 and E7 viral oncoproteins bind to host regulatory proteins, presumably leading to degradation of p53 protein and inactivation of the retinoblastoma gene protein Rb, two essential tumor suppressor gene products. 3 These interactions, enhanced by the viral genome integration, lead to a deregulation of the cell cycle that is manifested by an abnormal expression of cell cycle-associated proteins, among them p16, a cyclin-dependent kinase inhibitor that downregulates progression through the G1-S transition checkpoint of the cell cycle. 4, 5 As a consequence, classic vulvar intraepithelial neoplasias are typically diffusely p16 ink4 positive. In contrast, approximately 60% of vulvar carcinomas are not associated with HPV and are often coupled to a precursor lesion designated simplex or differentiated vulvar intraepithelial neoplasias. 2, 6 As a result of their mature appearance and lack of the conspicuous atypia attributed to classic vulvar intraepithelial neoplasias, differentiated vulvar intraepithelial neoplasias are not as well defined. They typically develop in association with lichen sclerosus and lichen simplex chronicus. Previous studies had revealed the presence of Tp53 mutations in some of these tumors. [7] [8] [9] Clinicopathological overlap between HPV-associated and non-HPV-associated tumor may be observed in some cases, in which immunohistochemistry with p16 and HPV testing are more reliable than morphology for classification of both vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma. 10, 11 In the HPV-related pathway, classic VIN is generally accepted as a precursor of invasive carcinoma. Although differentiated vulvar intraepithelial neoplasia is a likely candidate for precursor of HPVnegative vulvar squamous cell carcinoma and has been implied by strong p53 immunohistochemical signal, the genetic relationship between these two entities is not well understood because of molecular heterogeneity in both cancers and precursors. [12] [13] [14] [15] In this study, we aim to (1) determine whether differentiated vulvar intraepithelial neoplasias contain Tp53 mutations, (2) correlate Tp53 mutation status with p53 immunostaining, and (3) establish whether differentiated vulvar intraepithelial neoplasias and vulvar squamous cell carcinomas share identical Tp53 mutations.
Materials and methods

Case Selection
Eleven consecutive cases from 2005 to 2008 originally diagnosed as differentiated vulvar intraepithelial neoplasia were selected. Specimens ranged from biopsies to radical surgical products and in six cases the vulvar intraepithelial neoplasias were associated with vulvar squamous cell carcinoma.
Immunohistochemistry
Cases were sectioned and stained for p53 and p16 INK4 . Four-micrometer sections of formalin-fixed, paraffin-embedded tissue were cut and placed on glass slides. Tissue sections were de-paraffinized and rehydrated through xylene and graded alcohols. Endogenous peroxidase activity was blocked by incubation in a solution of 3% hydrogen peroxide in 100% alcohol (1:1). Heat-induced antigen retrieval was carried out with Dako Target Retrieval Solution, pH 6.0, and pressure cooker heated (122-125 1C) for 30 s at 15-24 p.s.i. Sections were incubated 40 min at room temperature with antibodies directed against p53 (clone: E6H4, MTM laboratories AG, Heidelberg, Germany) at a 1:1200 dilution, and against p16 INK4 (clone 16P07, NeoMarkers Fremont, CA, USA) at an unknown concentration (pre-diluted). Application of the primary antibodies was followed by incubation 30 min with Dako Labeled Polymer-HRP anti-mouse IgG as a secondary antibody, and visualized with 3, 3 0 -diaminobenzidine (DAB) as a chromogen (Envision þ System) and Mayer hematoxylin counterstaining. Sections containing normal epithelia were included in each run to assess background. Positive slide controls containing colon adenocarcinoma (for p53) and cervical intraepithelial neoplasia (for p16 INK4 ) were included in each staining run.
In addition, serial sections from a small series of p53-positive differentiated vulvar intraepithelial neoplasias, vulvar squamous cell carcinomas, and normal mucosa were stained for p63, a marker of basal or immature squamous cells that has been linked to stem cell characteristics. 16 The purpose was to determine the limits of p53 immunostaining in these epithelia using an objective marker for cell differentiation. Immunostaining was performed with the 4A4 clone of p63 (courtesy of Frank D McKeon), as described earlier. 17 
HPV Detection
All 12 cases were analyzed for HPV DNA. The detection was carried out using polymerase chain reaction (PCR) on target DNA extracted from formalin-fixed, paraffin-embedded tissue samples. Briefly, 3 to 10 eight-micron sections of paraffinembedded tissue were placed in a microcentrifuge tube and incubated with Proteinase K in a digestion buffer overnight at 62 1C. After the addition of Chelex (Bio-Rad Laboratories, CA, USA), specimens were boiled and centrifuged, and the aqueous phase was removed for testing.
The HPV DNA was detected using 16E7A and 16E7B primers. 18 These primers were designed to detect HPV 16 E7 DNA, which is found in the majority of HPV-positive vulvar intraepithelial neoplasias. These primers detect a 224-bp section of the E7 region of the HPV DNA. Amplifications were carried out under the following conditions: Initial denature of 2 min at 94 1C, followed by 35 cycles of 94 1C for 30 s, 55 1C for 30 s, and 72 1C for 1 min; and a final extension of 72 1C for 5 min. Reaction products were run on 5% Tris/Boric Acid/EDTA (TBE) precast acrylamide gels (Bio-Rad Laboratories) at 120 V for 50 min. The gels were then stained with ethidium bromide mixed in 1 Â TBE for 15 min and then washed with water. Gel images were acquired using UV Light Chamber (Bioimaging Systems). INK4A stained slides were reviewed by two pathologists (APP and CPC). The immunoreactivity of p53 and p16
INK4A in vulvar intraepithelial neoplasia lesions and when present, in their adjacent vulvar squamous cell carcinoma, was scored as positive or negative based on the localization and extent within the epithelium. A positive score for p53 required strong nuclear staining that obscured nuclear detail. Positive cases were further classified according to stain location as (1) when restricted to the basal layer, and (2) when present in supra-basal layers. A positive score for p16 required strong and diffuse (more than 90% of the lesion) nuclear and cytoplasmic staining. Positive cases were sub-classified as (1) when signal was confined to the lower half of the epithelium, and (2) when it was transepithelial. Fields for laser microdissection were selected based on H&E and p53 stains and included multiple tissue sites representing normal controls (three lymphoid aggregates and seven squamous epithelial), differentiated vulvar intraepithelial neoplasia (n ¼ 18), and vulvar squamous cell carcinoma (n ¼ 6). Two p53 immunohistochemistry-positive cases (#s 4 and 6) had the upper and lower regions of the differentiated VIN epithelium individually microdissected. Other two cases (#s 2 and 5), had in addition, the peripheral and central regions of its associated tumor nests individually microdissected based on the p53 expression.
Laser Capture Microdissection and DNA Extraction
Sections (8 mm) for laser capture microdissection were cut and placed on glass slides coated with PEN membrane (Arcturus Bioscience). A section of each specimen was then stained with H&E and examined microscopically to confirm the diagnosis. Targeted areas were selectively microdissected using the PALM microbeam instrument (Carl Zeiss Microimaging, Munich, Germany) according to standard protocols. Cells were captured on a thin film attached to a plastic cap, which was then attached to an Eppendorf tube containing 50 AL digestion buffer (40 mMol/l Tris-HCl (pH 8.0), 1 mmol/l EDTA, 0.5% Tween 20, and 0.5 Ag/AL proteinase K) and incubated at 37 1C in inverted position for 24 to 48 h. After a brief spin at 1000 r.p.m., the supernatant was transferred into a 1.5-ml centrifuge tube. The proteinase K was inactivated at 95 1C for 10 min and the solution was kept at À20 1C in aliquot.
Analysis for Tp53 Mutations
All samples were analyzed for Tp53 mutations. Genomic DNA was amplified by PCR using tailed primers designed to amplify exons 2 to 11 of Tp53. A secondary amplification was performed using primers specific to the tail sequences used in the primary amplification. PCR products were then sequenced from both strands using the same tailed primers. Data were analyzed using the Mutation Surveyor program (Soft Genetics, State College, PA, USA). Candidate mutations identified using the software was compared with the Universal Mutation Database (http://www.umd.be:2072/IFAMTP53A. shtml) for cancer-associated Tp53 mutations.
As formalin fixation can introduce spurious mutations into somatic DNA, all Tp53 mutation-positive exons were re-sequenced from a replicate PCRamplified product. Samples were scored as positive for Tp53 mutation only if an identical mutation was identified in products of both amplifications. 19 
Results
Most Differentiated Vulvar Intraepithelial Neoplasias are Associated with Tp53 Mutations
Micro-dissected vulvar intraepithelial neoplasia areas of the 12 cases, Tp53 mutations and their effects in translation, immunostain (p53 and p16 INK4A ) results, and HPV status were summarized in Table 1 . In 6 out of 10 cases of differentiated vulvar intraepithelial neoplasia, at least one differentiated vulvar intraepithelial neoplasia focus contained one or more Tp53 mutations.
Differentiated Vulvar Intraepithelial Neoplasias with Missense Mutations are p53 Immunohistochemistry Positive
Of the six cases with Tp53 mutations, four were p53 immuno-positive and two were negative. In all four p53 immunohistochemistry positive, the mutation effect was either missense or splice, while deletions were found in the other two p53 immunohistochemistry-negative differentiated vulvar intraepithelial neoplasias. Case images were illustrated in Figure 1 . An example of differentiated vulvar intraepithelial neoplasia that was p16 negative, p53 strongly positive, and showed the same mutation in three different micro-dissected areas is shown in Figures 1a-c. In contrast, Figure 1d shows a strong, trans-epithelial p16 signal in a case of classic vulvar intraepithelial neoplasia included for comparison. Figure 2 illustrates a case with differentiated vulvar intraepithelial neoplasias dissected from three distinctive areas plus the associated vulvar squamous cell carcinoma that showed strong positivity for p53, as well as the same Tp53 mutation (Table 2 ). In the p53 immunohistochemistry-positive differentiated vulvar intraepithelial neoplasias in which the basal cells were positive, Tp53 sequence analysis of microdissected regions showed the following: (1) identical mutations in three out of three areas of differentiated vulvar intraepithelial neoplasia in case #4, and in two out of three areas of differentiated vulvar intraepithelial neoplasia and in one area of invasive vulvar squamous cell carcinoma in case #5; (2) disparate mutations and disparate plus similar mutations were identified in two areas of differentiated vulvar intraepithelial neoplasia and one area of vulvar squamous cell carcinoma, respectively, in case #2 (3) absence of Tp53 mutations in the differentiated vulvar intraepithelial neoplasia of case #6.
Expression of Mutated p53 Protein, when Detected, is Confined to the Immature Keratinocytes and Degraded as a Function of Keratinocyte Maturation
As p53 staining is confined to the basal-type cells in differentiated vulvar intraepithelial neoplasia, epithelial foci from the lower and upper layers were separately microdissected and sequenced. Samples derived from the higher p53 immunohistochemistry-negative epithelial layers of one out of two areas of differentiated vulvar intraepithelial neoplasia in case #2 and two out of three areas of differentiated vulvar intraepithelial neoplasia in case #4 were also mutation positive, consistent with derivation from the same clone as the p53-positive basal cells. Staining with p63, a p53 homolog that is a marker for immature keratinocytes revealed an identical pattern of nuclear distribution (Figure 3) . Combined with the sequencing data, this supports the concept that mutated p53 protein is degraded as a function of keratinocyte maturation.
Discussion
This study has confirmed that most differentiated vulvar intraepithelial neoplasias are associated with Tp53 mutations or deletions, that p53 immunohistochemistry positivity is dependent on the nature of the mutation, that the vulvar mucosa is prone to the emergence of more than one Tp53 mutation, and that in some instances, the vulvar squamous cell carcinoma is genetically linked to its presumed precursor (differentiated vulvar intraepithelial neoplasia). 7, 9 Predictably, a majority (70%) of the mutations found in differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma were located in exons previously shown to contain the highest incidence of mutations in vulvar squamous cell carcinoma, exons 5 through 9. 9, 19, 20 Four out of five differentiated vulvar intraepithelial neoplasia-associated carcinomas were Tp53 mutation-positive.
Interpretation of p53 immunohistochemistry positivity requires some care. Immunohistochemistry over-expression of p53 has been reported in lichen simplex chronicus, lichen sclerosus, and differentiated vulvar intraepithelial neoplasia adjacent to HPV-negative vulvar cancer. 7, 11, 12, 19, 20 The immunohistochemistry signal observed in lichen simplex chronicus and lichen sclerosus is usually weak and confined to a single, un-expanded layer of basal Tp53 mutations in differentiated vulvar intraepithelial neoplasias cells. 12, 21 In these entities, Tp53 mutations are usually not found; therefore, the p53 protein signal has been attributed to upregulation of p53 wild-type protein, possibly reflecting a stress response to inflammation or ischemia. 21 In contrast, p53 immunohistochemistry signals in differentiated vulvar intraepithelial neoplasia have been described as strong and constant, and often involving more than a single layer of basal-type cells, as observed in the majority (4/5) of our cases (Figures 1b, 2a-c) . 12, 22, 23 The immunohistochemistry signal observed in this context has been presumed to derive from an abnormal (mutated) p53 protein. This argument is supported by: (1) a significant association of p53 immunoreactivity with loss of heterozygosity (LOH) at different chromosomal loci, including the Tp53 locus, 17p13; and (2) the detection of Tp53 mutations in p53 immunohistochemistry-positive atypical lichen sclerosus (or differentiated vulvar intraepithelial neoplasia). 8, 19, 20 This study revealed Tp53 mutations in most but not all differentiated vulvar intraepithelial neoplasias. The two p53 immunohistochemistry-negative cases could be explained by Tp53 deletions that would lead to premature termination of translation, whereas the four p53 immunohistochemistry-positive cases with missense mutations were able to accumulate abnormal p53 protein. The fact that disparate foci of differentiated vulvar intraepithelial neoplasia presented with different Tp53 mutations in our cases is consistent with the hypothesis that the vulvar epithelium is prone to multiple events leading to independent cell populations with these mutations. Evidence linking these mutations to adjacent vulvar squamous cell carcinomas has been limited. One previous study showed shared Tp53 mutations in both lichen sclerosus and vulvar squamous cell carcinoma. Otherwise, the link between differentiated vulvar intraepithelial neoplasia and keratinizing vulvar squamous cell Tp53 mutations in differentiated vulvar intraepithelial neoplasias AP Pinto et al carcinoma has been inferred from prospective follow-up studies or shared patterns of allelic loss. 24 We were able to show that coexisting differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma shared the same mutation in two of our cases. Thus, some foci of differentiated vulvar intraepithelial neoplasia represent direct cancer precursors while others are independent events, in keeping with previous studies of allelic imbalance. 13, 15 It should be emphasized that although shared Tp53 mutations alone will provide evidence of a shared cell of origin for differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma, it is an oversimplification to assume that the Tp53 mutation is the initial carcinogenic event.
Vanin et al were able to show LOH of Tp53 in vulvar squamous cell carcinoma and lichen sclerosus in the absence of mutations. 20 They suggested that actual Tp53 mutations were usually late events and that the LOH affecting Tp53 also affected another tumor suppressor gene on 17p. 20 The presence of p53 immunopositivity in only the immature component of the differentiated vulvar intraepithelial neoplasia is in contrast to other neoplasms with p53 mutations and we were able to confirm that the same p53 mutation was present in all of the epithelial layers, consistent with a shared genetic identity. This maturationdependent loss of p53 immunostaining indicates that, similar to p63, this mutant protein is vulnerable to degradation in maturing keratinocytes. 25 Thus, the vertical extent of p53 staining can be expected to vary according to epithelial differentiation as shown in Figures 1-3 , and the number of epithelial layers showing staining alone cannot be expected to predict whether a p53 mutation is or is not present.
In summary, this study was able to establish that (1) distinct foci of differentiated vulvar intraepithelial neoplasia contain varied Tp53 mutations consistent with multiple neoplastic clones; (2) these neoplastic foci will be p53 immunopositive when missense mutations are present, and p53 immunonegative in the absence of mutations or when deletion or nonsense mutations are present; (3) differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma share identical Tp53 mutations, supporting a pathogenetic connection between them; and (4) the restraint of p53 staining to immature cell nuclei is consistent with maturation-dependent degradation of mutant p53 protein, similar to its homolog p63. 16 
